Exhibitor

Pulmonx helps improve the lives of patients suffering from emphysema with its minimally-invasive, personalized treatment and diagnostic tools. The company’s commercial portfolio includes the Zephyr Endobronchial Valve (EBV), the most-studied device for endoscopic lung volume reduction; the Chartis System, an assessment tool that identifies collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based quantitative computed tomography (CT) analysis service. These tools enable physicians to successfully predict outcomes and provide optimal treatment for emphysema patients.